.jpg)
Blood platelets (thrombocytes) interact with matrix components (perlecan) in the spleen.
Image Credit: © LMU Klinikum
Scientific Frontline: Extended "At a Glance" Summary: Splenic Regulation of Platelet Activation
The Core Concept: The spleen functions as a biological filter and quality-control checkpoint that monitors and removes overactivated blood platelets (thrombocytes) from systemic circulation.
Key Distinction/Mechanism: While circulating through the spleen, platelets receive activating signals from splenic tissue and counteracting inhibitory signals from their own G6b surface receptors. In normal, resting platelets, the inhibitory signals dominate, allowing them to return to the bloodstream; however, if platelets are heavily overactivated, the inhibitory signals are insufficient, causing the platelets to adhere within the spleen and undergo clearance by specialized phagocytes.
Major Frameworks/Components:
- Blood platelets (thrombocytes) and their role in wound closure and thrombotic events.
- The G6b receptor located on the surface of platelets, which is responsible for transmitting inhibitory signals.
- Splenic tissue matrix components, which generate platelet-activating signals.
- Splenic phagocytes, which are responsible for the physical removal of adherent, overactivated platelets.
Branch of Science: Hematology, Immunology, Cardiology, and Cell Biology.
Future Application: This mechanism presents a novel pathway for the development of targeted therapies that selectively clear overactivated platelets, potentially treating conditions like sepsis and thrombosis without increasing the general risk of bleeding associated with broad-spectrum platelet inhibitors such as Clopidogrel.
Why It Matters: This discovery explains why patients who have undergone a splenectomy possess an elevated risk of blood clots and severe inflammatory responses, highlighting the organ's essential, previously unrecognized role in systemic hemostasis and vascular protection.
.jpg) |
| The Nicolai research group (from left to right: Laun, Nicolai, Zhang). Photo Credit: © LMU Klinikum |
Activated by injuries, blood platelets (thrombocytes) help wounds close quickly. When activated in an uncontrolled manner, however, they can trigger heart attacks and strokes and promote tissue damage during infections. Until now, little has been known about how the body regulates this sensitive balance.
A research team from the Medical Clinic and Polyclinic I (Cardiology) at LMU University Hospital, led by Privatdozent Dr. Leo Nicolai and Professor Steffen Massberg, along with lead authors Lisa Laun, Dr. Alexander Leunig, and Felix Zhang, has discovered a previously unknown protective mechanism of the spleen.
Interestingly, this mechanism plays a role in many different disease models and could therefore also offer new approaches for treating various diseases, such as sepsis and thromboses.
Quality Control in the Spleen
The researchers showed that the spleen acts as a quality-control checkpoint, allowing resting platelets to enter the bloodstream while retaining and clearing platelets that are already strongly activated. The absence of this filter mechanism in animal models led to increased thromboses, lung injuries, and pulmonary embolisms.
The researchers also found supporting evidence in heart attack patients, in whom the spleen becomes enlarged and accumulates activated platelets. In other words, the protective mechanism appears to work in humans as well.
The scientists discovered that at the molecular level, platelets receive activating signals from splenic tissue while passing through the spleen. At the same time, the G6b receptor located on the surface of the platelets sends inhibitory signals that counteract this activation. This allows resting platelets to return to the bloodstream.
For platelets that are already strongly activated, however, the inhibitory signals are no longer sufficient to neutralize the activation. They remain activated and adhere within the spleen, where they are removed by specialized phagocytes. The results provide a possible explanation for why people without a spleen have an increased risk of blood clots and severe illness during inflammation: They lack this natural protective filter.
Prospect of More Targeted Therapies Against Overactivated Platelets
Millions of people take platelet-inhibiting drugs, such as aspirin and clopidogrel, to prevent heart attacks or strokes. Because these drugs inhibit the activation of all platelets, however, they often increase bleeding risks as well. The natural protective mechanism discovered by the researchers could, in the long term, pave the way for more targeted therapies that primarily disable overactivated platelets and leave normal blood clotting largely intact.
“Interestingly, this mechanism plays a role in many different disease models and could therefore also offer new approaches for treating various diseases, such as sepsis and thromboses,” observes Leo Nicolai. His team plans to further investigate the possible therapeutic use of this mechanism for human diseases.
Published in journal: Science
Title: Splenic regulation of systemic platelet activation state
Authors: Lisa Laun, Alexander Leunig, Felix Zhang, Sezer Akgöl, Dario Rossaro, Matthias P. Fabritius, Afra Anjum, Lennart Kreutz, Nathalie Mackert, Gabriel H.M. Araujo, Shaan Mahameed, Craig Balmforth, Marie-Louise Hoffknecht, Magdalena Mader, Konstantin Hoffmann, Justus Reittinger, Johanna Knechtel, Nellie M. Kwabla, Maité Mulkers, Michael Schmid, Jean Solarz, Hannah Niederdorfer, Raphael Escaig, Robin Dewender, Heiko Schulz, Frederick Klauschen, Konstantin Stark, Florian Gaertner, David E. Newby, Bernhard Nieswandt, Filip K. Swirski, Zoltan Nagy, Alexandra Mazharian, Rainer Kaiser, Yotis A. Senis, Steffen Massberg, and Leo Nicolai
Source/Credit: Ludwig-Maximilians-Universität München
Edited by: Scientific Frontline
Reference Number: bio091826_01
